

EXHIBIT B
THE CLAIMS THAT WILL BE PENDING UPON ENTRY OF THE AMENDMENT
FILED: September 27, 2002

22. A method for enhancing the effectiveness of nicotine replacement therapy in an individual in need of such treatment consisting essentially of:

administering to an individual in need of nicotine replacement therapy a therapeutically effective amount of

(a) nicotine; and

(b) one or more substances selected from the group consisting of (i) substances which inhibit CYP2A activity; (ii) substances which inhibit transcription, and/or translation of the gene encoding CYP2A activity; and (iii) substances which delete all or a portion of the gene encoding CYP2A,

wherein (a) and (b) are administered contemporaneously and (b) is administered in an amount of about 0.01 mg/kg to 80 mg/kg.

23. A method according to claim 22 wherein said substance inhibits CYP2A6 and is methoxsalen, psoralen, tranylcypromine, pilocarpine, coumarin, chromone, esculetin, phenelzine, paroxetine, selegiline, or pargyline.

24. A kit in the use in the method of claim 22 or 23 comprising (a) nicotine and (b) one or more substances selected from the group consisting of (i) substances which inhibit CYP2A activity; (ii) substances which inhibit transcription, translation of the gene encoding CYP2A, or both; and (iii) substances which delete all or a portion of the gene encoding CYP2A,

wherein (a) and (b) are administered contemporaneously.

35. The method for enhancing the effectiveness of nicotine replacement therapy according to claim 22 further comprising substances which inhibit CYP2B6 activity, substances which inhibit transcription and/or translation of the gene encoding CYP2B6, or a combination thereof.

36. The method according to claim 35, wherein the substances is selected from phenylethyl amines, diphenylbarbiturates, diethyl substituted barbiturates, or hydantoins.